MDM2 and leukemia: Taken together, these results suggest that MDM2 may be a therapeutic target to increase TKI-mediated apoptosis and that combining PI3K/mTOR inhibitor and TKI may prove an effective novel therapeutic strategy in TKI-resistant BCR-ABL1 positive leukemia.